CUBT (Curative Biotechnology) Receivables Turnover: 0.00 (As of Mar. 2023)


What is Curative Biotechnology Receivables Turnover?

Curative Biotechnology CUBT +20.83% Receivables Turnover is 0.00 as of Mar. 2023.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Curative Biotechnology's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Curative Biotechnology's average Accounts Receivable for the three months ended in Mar. 2023 was $0.00 Mil.

Curative Biotechnology  (OTCPK:CUBT) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Curative Biotechnology Receivables Turnover Related Terms

Curative Biotechnology Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology Receivables Turnover Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Receivables Turnover
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CUBT vs ORGS, SNSE, TNXP: Receivables Turnover Comparison

For the Biotechnology subindustry, Curative Biotechnology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's Receivables Turnover falls into.


Curative Biotechnology Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Curative Biotechnology's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Receivables Turnover (A: Dec. 2022 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2022 ) / ((Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Curative Biotechnology's Receivables Turnover for the quarter that ended in Mar. 2023 is calculated as

Receivables Turnover (Q: Mar. 2023 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Mar. 2023 ) / ((Accounts Receivable (Q: Dec. 2022 ) + Accounts Receivable (Q: Mar. 2023 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Curative Biotechnology (CUBT) has a Receivables Turnover of 0.00 as of Mar. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's Receivables Turnover too high?
Curative Biotechnology's current Receivables Turnover is 0.00.
How does Curative Biotechnology's Receivables Turnover compare to ORGS and SNSE?
Curative Biotechnology's Receivables Turnover of 0.00 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curative Biotechnology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curative Biotechnology's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current Receivables Turnover is 0.00 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.